Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03412513
Other study ID # PaDOMi Study
Secondary ID
Status Recruiting
Phase Phase 4
First received January 21, 2018
Last updated January 29, 2018
Start date July 17, 2017
Est. completion date December 31, 2018

Study information

Verified date January 2018
Source Seoul National University Hospital
Contact Seung-June Oh, MD
Phone +82-2-2072-2421
Email sjo@snu.ac.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to see the study drug, Mirabegron, is safe and effective in treating symptoms of Overactive Bladder in patients with Parkinson's disease.


Description:

This study is a randomized 1:1 placebo-controlled 12-week study of Mirabegron in 144 Parkinson's subjects the age of 40 to 80 with overactive bladder. Active drug will be Mirabegron 50mg daily. Subjects will be enrolled based on response to an overactive bladder questionnaire at visit 1. Enrolled subjects will have 3 study visits to the clinic as well as 1 phone visit.


Recruitment information / eligibility

Status Recruiting
Enrollment 144
Est. completion date December 31, 2018
Est. primary completion date July 16, 2018
Accepts healthy volunteers No
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria:

- Subject who signed a consent form approved from IRB(Institutional Review Board) or IEC(Independent Ethics Committee)

- Diagnosis of Parkinson's disease by a neurologist

- taking a Parkinson's medications stably during 4 weeks preceding screening

- 40 Years to 80 Years, Male and Female

- Patient has overactive bladder symptoms more than 4 weeks preceding screening.

- OABSS questionnaires total score= 3 and entries of urinary urgency score= 2

- The expanded disability status scale = 7

Exclusion Criteria:

- Subjects who have any intervention and operation which can influence on study such as bladder augmentation, vesical sphincter, artificial sphincter, intravesical botulinum toxin treatment etc.

- Use of indwelling catheter or self-catheterization

- acute urinary tract infection or urolithiasis at screening

- History of chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy, or previous or current malignant disease of the pelvic organs

- total volume urine > 3L a day

- Screening post-void residual > 200ml

- Nonpharmacological therapy within the previous 4 weeks of screening

- screening blood pressure >180 systolic or 110 diastolic

- subjects who have orthostatic hypotension, syncope, hypokalemia, or angle-closure glaucoma

- Clinically Significant ECG in recent year

- Screening estimated glomerular filtration rate (eGFR) < 29, AST ( aspartate aminotransferase ) or ALT ( alanine aminotransferase ) > 2x upper limit of normal, ?-GT(gamma-glutamyl transferase) > 3xULN

- take following medication additionally or change the dose: previous 4weeks of screening to end of the study (tamsulosin/silodosin/terazosin, baclofen, diazepam, amitriptyline, DDAVP/desmopressin) previous 12weeks of screening to end of the study (finasteride, dutasteride)

- Use ß2- adrenoreceptor agonist, loop diuretic, CYP 3A4 inducer, CYP 2D6 narrow therapeutic index, CYP 3A4 inhibitor, antifungal agent, antiarrhythmic agent

- History of allergy to Mirabegron and beta-adrenergic receptor

- Use of one of the anti-cholinergic bladder medications such as Propiverine / tolterodine / trospium / darifenacin / solifenacin / fesoterodine and mirabegron within 14 days of the screening visit. Subjects who have used one of these medications in the past but discontinued it at least 14 days prior to the screening visit can be enrolled.

- women who have potential to become pregnant during the course of the study

Study Design


Intervention

Drug:
Mirabegron
Mirabegron 50mg po daily for 12 weeks to Active Comparator group, and 4 weeks(from visit 4 to visit 5) to Placebo comparator group.
Placebo
Placebo po daily for 8 weeks to Placebo comparator group.

Locations

Country Name City State
Korea, Republic of Kyungpook National University Hospital Daegu
Korea, Republic of Hallym University Medical Center Gyeonggi-do
Korea, Republic of Seoul National University Bundang Hospital Gyeonggi-do
Korea, Republic of Severance Hospital Seoul
Korea, Republic of SMG-SNU Boramae Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the total score of Overactive Bladder Symptom Scale(OABSS) Change in the total score of Overactive Bladder Symptom Scale(OABSS) from baseline(Visit 2) to Visit 4 Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Secondary Change in the total score of OABSS(Overactive Bladder Symptom Scale) Change in the total score of OABSS, Visit 3, Visit 4 and Visit 5 Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Secondary Change in the total score of IPSS(International Prostate Symptom Score) Change in the total score of IPSS and bothersome score, Visit 3, Visit 4 and Visit 5 Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Secondary Change in the total score of OAB-q short form Change in the total score of OAB-q short form,Visit 3, Visit 4 and Visit 5 Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Secondary Change in the total score of PPBC(Patient Perception of Bladder Condition) Change in the total score of PPBC, Visit 3, Visit 4 and Visit 5 Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Secondary Change in the total score of TSQ (Treatment Satisfaction Questionnaire) Change in the total score of TSQ, Visit 3, Visit 4 and Visit 5 Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Secondary Change in the total score of GRA (Global Response Assessment) Change in the total score of GRA, Visit 3, Visit 4 and Visit 5 Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Secondary Change in the score of BSW (Benefit, Satisfaction and Willingness to Continue Questions) Change in the score of BSW, Visit 4 and Visit 5 Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Secondary Change in the Mean Frequent Urination Change in the Mean Frequent Urination, Visit 3 and Visit 4 Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Secondary Change in the Mean number of Urinary urgency Change in the Mean number of Urinary urgency, Visit 3 and Visit 4 Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Secondary Change in the Mean number of Urinary incontinence Change in the Mean number of Urinary incontinence, Visit 3 and Visit 4 Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A